473: Sixty years of cells that stop dividing

From Base by Base · 00:19:38

Show by Gustavo Barra

Klaver M et al., The EMBO Journal - In 1961, Hayflick and Moorhead showed that normal human fibroblasts divide only a finite number of times. This episode follows a review of the six decades since, as senescence moved from a cell-culture limit to a tumor-suppressive stress response, a tissue-remodeling program, a contributor to aging and disease, and a target for therapy. Key terms: cellular senescence, SASP, senolytics, senomorphics, aging. Study Highlights:This review traces cellular senescence from the Hayflick limit of 1961 through telomere shortening, biomarkers and oncogene-induced senescence. The senescence-associated secretory phenotype revealed that senescent cells actively communicate with their tissues, and later work showed there is no single universal SASP. Genetic ablation in mice showed that senescent cells can contribute causally to age-related decline, while other studies showed roles in wound healing, development and tissue repair, and one p16-lineage study reported detrimental effects on the liver. Senolytics such as dasatinib plus quercetin and senomorphics followed, but UBX0101 failed to show significant benefit in Phase 2 and UBX1325 missed its Phase 2b primary endpoint. The authors identify the lack of validated biomarkers of target engagement as the major bottleneck in clinical senotherapy. Conclusion:The authors conclude that senescence is neither inherently beneficial nor inherently detrimental, and that its consequences depend on context, which senescent cells are involved, and how long they persist. This is a narrative review, not a new experiment, and much of the causal evidence comes from mouse models, with human trials so far early, limited by size or design, or unsuccessful. Article title:Cellular senescence: six decades of discovery and reinvention First author:Klaver M Journal:The EMBO Journal DOI:10.1038/s44318-026-00922-w Reference:Klaver M., Steeneken L.S., Veeningen N., Altulea A., Demaria M. Cellular senescence: six decades of discovery and reinvention. The EMBO Journal, 45, 7307-7325. (2026). https://doi.org/10.1038/s44318-026-00922-w License:This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support:Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming:❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/cellular-senescence-six-decades-review QC:This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary:- sentences checked: 183- supported by the article: 182- flagged and reviewed by a human: 1- metadata checks passed: 4 of 4 QC result: Pass. Chapters (00:00:03) - Introduction: The Hayflick Discovery(00:00:44) - About This Episode and Paper(00:02:30) - Telomere Shortening as a Mechanism(00:03:11) - Finding Markers for Senescence in Tissue(00:03:58) - Oncogene-Induced Senescence and Tumor Suppression(00:04:41) - Multiplying Triggers of Senescence(00:05:29) - Discovery of the SASP Secretory Phenotype(00:06:18) - Complexity and Diversity of SASP Programs(00:07:08) - Testing Causality: Senescent Cell Clearance Models(00:08:25) - Beneficial Roles in Healing and Repair(00:09:00) - Developmental Senescence Discovery(00:10:12) - Senescence and the Aging Hallmarks Framework(00:10:51) - The Persistence Paradox and Disease Links(00:11:37) - Immune Clearance of Senescent Cells(00:12:37) - Immune Evasion and Immunosenescence(00:13:08) - Senolytics: Targeting Senescent Cells(00:13:59) - Senomorphics: Suppressing the SASP(00:14:47) - Early Human Clinical Trials(00:15:32) - Clinical Setbacks and Failures(00:16:16) - The Biomarker Bottleneck(00:17:04) - Toward Precision Senescence Targeting(00:17:51) - Conclusion: Context-Dependent Senescence(00:18:28) - Future Directions and Closing Thoughts

More episodes of Base by Base

More episodes

podsearch is a free, independent podcast search engine. Read about podsearch, the privacy policy or contact us.